Source Concord: suspension due to the involvement of Wei Zexi event negative reports | Wei Zexi events _ news
Legal evening news (section coordinators: Zhu Shunzhong depth Reporter: Zhang Rui) this morning, by night (app ID:fzwb_52165216) reporter was informed that was involved in a "Wei Zexi event" source in the a-share listed companies Union temporarily suspend business for one day.
It said in a statement released this morning: the company applies for suspension of the relevant verification matters. Legal evening news (app ID:fzwb_52165216) reporter then called the source Association and Secretary of the Board of the phone, its staff, "said suspension is because the involvement of a Wei Zexi in the event of negative reports. ”
On March 4, 2016, the Union said in a statement in the source, by way of non-public offering of shares to 1.1 billion yuan Shanghai Ke Laixun 100% stakes. Shanghai Ke Laixun company provided armed police hospital with technical cooperation support unit biological tumor.
Public information, Ke Laixun actual controller Chen Xin. Chen Xinxi Fujian Putian people, his brother Chen Xinxian Singapore, Chairman of a medical investment group limited. Selection of media in recent days an "hospital in Putian" list, this Singapore medical group list. Ke Laixun website showing, in his capacity as Chairman, Chen Xinxian visited companies to guide our work.
Source Concord in suspension because of "Wei Zexi in negative coverage of the event"
"Emergency suspension is because the company is concerned about the significant negative reports, relating to the company are verified, verification will be announced to all investors an explanation. This major news involving our company will have a significant impact on the company's share price, did not know before, regardless of reset, and will bring great losses to investors. "This morning, sources in place de la Concorde to the Secretary of the Board staff responded by late journalist, interpretations will come out today," as soon as possible. "
For legal evening news (app ID:fzwb_52165216) asked "announcement is the company may resume" issue, the staff member said, whether the resumption depends on the specific contents of the notice, "the normally clear things up and conclusion, you can resume trading. But exactly when needed after the announcement on resumption. "He repeatedly stressed that" soon ".
According to the China Securities Regulatory Commission listed companies stop the resumption of relevant provisions, companies can apply to the stock exchange on resumption, resumption or no longer need the stock exchange approval; significant temporary suspension can only apply for one day, continued during the suspension, you must then apply to the stock exchange, exchange of the company's application for approval, agreed to continue the suspension.
Source source Concord in Concord is the full name of the cell genetic engineering corporation, registered in the Tianjin Binhai New area, the legal representative Li Defu. Official information source in Concord show: source in Union's operating range of life science and technology development, stem cell genetic engineering industry, venture capital, investment banking, investment advisory, domestic trade, import and export of goods and technology (except for special provisions); the main business for the main business of cell preparation storage services, genetic testing, a test reagent sales.
On March 4, 2016, the source in Concord has announced that, by way of non-public offering of shares to 1.1 billion yuan Shanghai Ke Laixun 100% stakes.
Putian, acquired companies contributed 1.1 billion yuan Shanghai Ke Laixun
Source Concord in gene engineering of the non-public offering of stock to raise money using feasibility analysis report (hereinafter referred to as report) appears in: Shanghai Ke Laixun's main business for cellular immunotherapy technology research and development, as well as cellular immune therapy for medical institutions to provide services, at present the company's cell-mediated immune cell types including treatment of technical services designed CIK, NK cells, and so on. Worth noting is that DC-CIK cellular immune therapy is "Wei Zexi events" heart of medical technology.
The above analysis report, source Union considered, although cellular immunotherapy industry regulatory system is still not perfect in China, development of Cellular therapy is still subject to certain restrictions, but with the improvement of relevant policies have been issued, industry regulatory system, cell-mediated immunity in the treatment industry in the rapid development and market demand, driven by, are expected to achieve faster development.
"Report", the source in Concord also refers to reason--in this private placement to buy Ke Laixun acquisition Ke Laixun, in line with the development strategy of the company, to further improve the company's entire value chain layout, contribute to the achievement of the company's sustainable development. Ke Laixun business into listed company after system through effective integration with existing technology, customer resources, and will help enhance synergies with listed companies ' existing business, promote sustainable development of listed companies, further enhancing the core competitive power of listed companies.
In addition, the source in Concord in the "analytical report" also believes that "Shanghai Ke Laixun strong profitability in 2015, revenue Ke Laixun 29,633.310,000 yuan, net profit was 4,001.900,000 yuan. After the acquisition is completed, Ke Laixun will bring new growth to the source in future performance of Concord. ”
Shanghai Ke Laixun Putian of company
Public information, Ke Laixun actual controller Chen Xin. Chen Xinxi Fujian Putian people, his brother Chen Xinxian Singapore medical investment group limited company Chairman, disclosed in recent days about the media in a "hospital in Putian's list", the group list. Ke Laixun website showing, in his capacity as Chairman, Chen Xinxian visited companies to guide our work.
These reports also mentioned that Ke Laixun history –
In October 2007, Ke Laixun jointly funded by Yang Yong, Lin Bihua monetary ways, when you set up a registered capital of 100,000 yuan. October 10, 2007, were approved by the Shanghai Municipal Administration for industry and Commerce Yangpu branch Ke Laixun registration application. Set up, Ke Laixun ownership structure is as follows: Yang Yong contributed 50,000, 50% shares. Lin Bihua invested 50,000 yuan, 50% shares.
In November 2007, November 14, 2007, Ke Laixun shareholders, capital increase resolution to 20 million Yuan, added registered capital from existing shareholders as per original stake money method. Ke Laixun modified articles as the above changes, and business registration. The capital increase is completed, Ke Laixun ownership structure is as follows: Yang Yong invested 10 million Yuan, 50% stake; Lin Bihua invested 10 million Yuan, 50% shares.
In June 2008, on June 1, 2008, Ke Laixun shareholders, agreed with Yang Yong, Ke Laixun 50% stake held by it (corresponding investment amounted to 10 million yuan) transfer to Chen Xinxi; Lin Bihua Ke Laixun 40% owned by its (the corresponding amount is 8 million yuan) transfer to Chen Xinxi; Lin Bihua it holds 10% shares (corresponding to contributions of 2 million yuan) transfer to wuning.
On June 1, 2008, Yang Yong, and Lin Bihua respectively and Chen Xinxi signed equity transfer agreement, respectively agreed Yang Yong will its holds of Ke Laixun 50% of equity (corresponds to funded amount for 10 million yuan), and Lin Bihua will its holds Ke Laixun 40% of equity (corresponds to funded amount for 8 million yuan) transfer to Chen Xinxi; Lin Bihua and wuning signed equity transfer agreement, agreed Lin Bihua will its holds 10% of equity (corresponds to funded amount for 2 million yuan) transfer to wuning.
Ke Laixun modified articles as the above changes, and business registration. After the stock transfer, Ke Laixun ownership structure changed to: Chen Xinxi invested 18 million Yuan, representing 90% shares; wuning invested 2 million Yuan, representing 10% shares.
On December 15, 2014, Ke Laixun shareholders, capital increase resolution to 100 million Yuan, all additional registered capital made with Chen in money method. On December 23, 2014, Ke Laixun modified articles as the above changes, and business registration.
The capital increase is completed, Ke Laixun ownership structure is as follows: Chen Xinxi invested 98 million Yuan, representing 98% shares; wuning invested 2 million Yuan, representing 2% shares.
Responsible editor: Kun Qu SN117
Article keywords:Wei Zexi events
I want feedback
Save a Web page
Legal evening news
中源协和:公司停牌确因卷入魏则西事件负面报道|魏则西事件_新闻资讯
法制晚报讯（稿件统筹：朱顺忠 深度记者： 张蕊） 今天上午，法晚（微信公号ID：fzwb_52165216）记者获悉，被卷入“魏则西事件”的A股上市公司中源协和临时停牌一天。
其今天上午发布的公告中称：公司申请停牌对相关事项进行核查。法制晚报（微信公号ID：fzwb_52165216）记者随后拨打了中源协和董秘电话，其工作人员称，“公司停牌确是因为卷入了魏则西事件的负面报道中。”
2016年3月4日，中源协和发布公告称，将通过非公开发行股票的方式以11亿元人民币收购上海柯莱逊100%股权。而上海柯莱逊公司正是向武警二院提供生物肿瘤技术支持的合作单位。
公开资料显示，柯莱逊的实际控制人为陈新喜。陈新喜是福建莆田人，其兄陈新贤为新加坡某医疗投资集团有限公司董事长。近几天来媒体大量选用的一份“莆田系医院”的名单中，这家新加坡的医疗投资集团位列其中。柯莱逊官网信息显示，陈新贤曾以集团董事长的身份前往公司指导工作。
中源协和停牌确因“魏则西事件负面报道中”
“紧急停牌就是因为公司关注到了重大的负面报道，公司正在核实有关的情况，核实后会发布公告，给所有投资人一个解释。这次的重大新闻报道中涉及到了我们公司，肯定对公司的股价有重大影响，没有调查清楚之前，置之不管，会给投资者带来巨大的损失。”今天上午，中源协和董秘工作人员向法晚记者回应称，解释公告今天就会出来，“肯定要尽快”。
对于法制晚报（微信公号ID：fzwb_52165216）记者询问的“公告出来是不是公司就可以复牌”的问题，这名工作人员称，是否复牌要看公告的具体内容，“正常情况下把事情调查清楚了，有结论了，就可以复牌了。但具体什么时候复牌还需要等公告出来后。”他再三强调“会很快”。
按照中国证监会有关上市公司停复牌的相关规定，公司能不能复牌要向证券交易所申请，复牌或者不复牌都需要证券交易所审批同意才可以；重大的临时性停牌只能申请一天，如继续停牌，必须再向证券交易所申请，交易所会对公司的申请进行审批，同意后才能继续停牌。
中源协和的全称是中源协和细胞基因工程股份有限公司，注册地为天津滨海新区，法人代表为李德福。中源协和的官方信息显示：中源协和的经营范围为生命科学技术开发、干细胞基因工程产业化、风险投资、投资理财、投资咨询、国内贸易、货物及技术进出口（除专项规定）；主营业务为从事的主要业务为细胞检测制备存储服务、基因检测、检测试剂的销售。
2016年3月4日，中源协和曾发布公告称，将通过非公开发行股票的方式以11亿元人民币收购上海柯莱逊100%股权。
作价11亿元收购莆田系公司上海柯莱逊
《中源协和细胞基因工程股份有限公司非公开发行股票募集资金使用可行性分析报告》（以下简称分析报告）中显示：上海柯莱逊的主营业务为开展细胞免疫治疗技术的研发，以及为医疗机构提供细胞免疫治疗技术服务，目前公司的细胞免疫治疗技术服务设计的细胞种类主要包括CIK、NK细胞等。值得注意的是，DC-CIK细胞免疫疗法正是“魏则西事件”的核心医疗技术。
在以上分析报告中，中源协和认为，虽然目前我国细胞免疫治疗行业监管体系尚不完善，细胞免疫治疗技术的发展仍受到一定限制，但未来随着相关政策陆续出台、行业监管体系的完善，细胞免疫治疗行业在技术的快速发展和市场需求的推动下，有望取得较快的发展。
“分析报告”中，中源协和还提到了收购柯莱逊的原因——本次非公开发行收购柯莱逊，符合公司的发展战略，有利于进一步完善公司的全产业链布局，有助于实现公司的可持续发展。柯莱逊的业务纳入上市公司体系后，通过与现有技术、客户资源等的有效整合，将有利于增强与上市公司现有业务的协同效应，促进上市公司业务持续发展，进一步提升上市公司核心竞争力。
此外，中源协和在“分析报告中”还认为“上海柯莱逊盈利能力很强，2015年，柯莱逊的营业收入为29，633.31万元，净利润为4，001.90万元。收购完成后，柯莱逊将为中源协和未来业绩带来新的增长点。”
上海柯莱逊为莆田系公司
公开资料显示，柯莱逊的实际控制人为陈新喜。陈新喜是福建莆田人，其兄陈新贤为新加坡某医疗投资集团有限公司董事长，近几天有关媒体披露的一份“莆田系医院的名单”中，该集团位列其中。而柯莱逊官网信息显示，陈新贤曾以集团董事长的身份前往公司指导工作。
上述可行性报告中，也提到了柯莱逊公司的历史沿革——
2007年10月，柯莱逊由杨勇、林碧花以货币方式共同出资设立，设立时注册资本为10万元。2007年10月10日，上海市工商行政管理局杨浦分局核准了柯莱逊的设立登记申请。设立时，柯莱逊的股权结构如下：杨勇出资5万，占50.00%股份。林碧花出资5万元，占50.00%股权。
2007年11月，2007年11月14日，柯莱逊召开股东会，决议增资至2，000万元，新增注册资本由现有股东按原持股比例以货币方式认购。柯莱逊根据上述变更修改了公司章程，并办理了工商变更登记。本次增资完成后，柯莱逊的股权结构如下：杨勇出资1000万元，占50.00%股权；林碧花出资1000万元，占50.00%股权。
2008年6月，2008年6月1日，柯莱逊召开股东会，同意杨勇将其持有的柯莱逊50%的股权（对应出资额为1，000万元）转让给陈新喜；林碧花将其持有柯莱逊40%的股权（对应出资额为800万元）转让给陈新喜；林碧花将其持有10%的股权（对应出资额为200万元）转让给武宁。
2008年6月1日，杨勇、林碧花分别与陈新喜签署《股权转让协议》，分别约定杨勇将其持有的柯莱逊50%的股权（对应出资额为1，000万元）、林碧花将其持有柯莱逊40%的股权（对应出资额为800万元）转让给陈新喜；林碧花与武宁签署《股权转让协议》，约定林碧花将其持有10%的股权（对应出资额为200万元）转让给武宁。
柯莱逊根据上述变更修改了公司章程，并办理了工商变更登记。本次股权转让后，柯莱逊的股权结构变更为：陈新喜出资1800万元，占90.00%股份；武宁出资200万元，占10.00%股份。
2014年12月15日，柯莱逊召开股东会，决议增资至10，000万元，新增注册资本全部由陈新喜以货币方式认购。2014年12月23日，柯莱逊根据上述变更修改了公司章程，并办理了工商变更登记。
本次增资完成后，柯莱逊的股权结构如下：陈新喜出资9，800万元，占98.00%股份； 武宁出资200万元，占2.00%股份。
责任编辑：瞿崑 SN117
文章关键词： 魏则西事件
我要反馈
保存网页
法制晚报